Ronald J. Fecek - Concepedia

Author

Ronald J. Fecek

University of Pittsburgh ORCID

Also Known As

Ronald Fecek, Ronald J Fecek, Ronald J. Fecek

Publications

682

Citations

H-Index

Concepts

All Affiliations

University of Pittsburgh UPMC Hillman Cancer Center Lake Erie College of Osteopathic Medicine University of Washington West Virginia University

About

Ronald J. Fecek is an author at University of Pittsburgh specializing in immunology, medicine, and immunomodulation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	95
2	Cell Biology	2	2	68
3	Engineering	1	1	11
4	Health Sciences	1	1	11
5	Allergy	1	1	10

Ronald J. Fecek

Publications

622

Citations

H-Index

Page 1

	Year	Citations
STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment Manoj Chelvanambi, Ronald J. Fecek, Jennifer L. Taylor, Journal for ImmunoTherapy of Cancer	2021	165
Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma Beatrice M. Razzo, Nils Ludwig, Chang‐Sook Hong, Carcinogenesis	2019	83
Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma Jae‐Yeon Choi, Wissam Beaino, Ronald J. Fecek, Journal of Nuclear Medicine	2018	75
CD40L Induces Functional Tunneling Nanotube Networks Exclusively in Dendritic Cells Programmed by Mediators of Type 1 Immunity Colleen R. Zaccard, Simon C. Watkins, Paweł Kaliński, The Journal of Immunology	2014	62
Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma Walter J. Storkus, Deena M. Maurer, Yan Lin, Journal for ImmunoTherapy of Cancer	2021	51
Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice Mintai P. Hwang, Ronald J. Fecek, Tianyue Qin, Journal of Controlled Release InflammationCancer ImmunosurveillanceB16-f10 MelanomaMelanomaImmunology	2019	44
Selective Induction of CTL Helper Rather Than Killer Activity by Natural Epitope Variants Promotes Dendritic Cell–Mediated HIV-1 Dissemination Robbie B. Mailliard, Kellie N. Smith, Ronald J. Fecek, The Journal of Immunology	2013	36
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8<sup>+</sup> effector T cell responses Dàlia Raϊch‐Regué, Kellsye P. Fabian, Alicia Watson, OncoImmunology	2016	25
Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice Kellsye P. Fabian, Nina Chi-Sabins, Jennifer Taylor, OncoImmunology ImmunologyImmunotherapeuticsImmunotherapyTumor BiologyTumor Immunology	2017	24
Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8 <sup>+</sup> T Cells Kellie N. Smith, Robbie B. Mailliard, Paolo Piazza, mBio	2016	19

Page 1